Deltex Medical has developed and proven the CardioQTM haemodynamic monitor system, which it produces in the UK and markets around the world. The CardioQTM is used on patients undergoing surgery and on critically ill patients to monitor the heart`s performance.
By identifying and monitoring any problems early, the CardioQTM allows doctors to optimize the patient`s haemodynamic status. Treating patients using the CardioQTM technology has been proven to help patients recover more fully and more quickly. Clinical studies show significant reductions in the length of hospital stay of up to 42%.
Patients all around the world are benefiting from the enormous medical and economic benefits of Deltex Medical`s technology -- CardioQTMs have already been sold into over 30 countries. With the positive support of many of the world`s leading medical experts in anaesthesia and critical care, Deltex Medical expects that haemodynamic optimization will become a global standard medical practice.
Deltex Medical intends to maintain and develop its market leading position and to build a substantial business as the wider medical community embraces the principles of haemodynamic optimization. Deltex Medical`s shares are traded in London on the Alternative Investment Market.
